{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:47:10Z","timestamp":1757616430297,"version":"3.44.0"},"reference-count":34,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Sex Reprod Health"],"accepted":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1136\/bmjsrh-2023-201949","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:20:14Z","timestamp":1693228814000},"page":"234-237","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Improving access to medicines for early medical abortion: learning from experiences of medicines licensing and service delivery"],"prefix":"10.1136","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-9079","authenticated-orcid":false,"given":"Sam","family":"Rowlands","sequence":"first","affiliation":[{"name":"Department of Medical Science & Public Health, Bournemouth University, Poole, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Harrison-Woolrych","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Otago, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"2025090511543865000_49.4.234.1","first-page":"237","article-title":"A constructivist vision of the first-trimester abortion experience","volume":"22","author":"Rowlands","year":"2020","journal-title":"Health Hum Rights"},{"key":"2025090511543865000_49.4.234.2","unstructured":"World Health Organization (WHO) . Abortion care guideline. Geneva WHO; 2022. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/349316"},{"key":"2025090511543865000_49.4.234.3","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc-2013-100862"},{"key":"2025090511543865000_49.4.234.4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/humupd\/dmaa026","article-title":"Access to and sustainability of abortion services: a systematic review and meta-analysis for the National Institute of Health and Care Excellence \u2013 new clinical guidelines for England","volume":"26","author":"O\u2019Shea","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2025090511543865000_49.4.234.5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/0162243920916781","article-title":"Misoprostol: the social life of a life-saving drug in global maternal health","volume":"46","author":"MacDonald","year":"2021","journal-title":"Sci Technol Hum Values"},{"key":"2025090511543865000_49.4.234.6","doi-asserted-by":"crossref","unstructured":"de Costa C , Carrette M . Early medical abortion. In: Rowlands S , ed. Abortion care. Cambridge: Cambridge University Press, 2014: 62\u201370.","DOI":"10.1017\/CBO9781107338623.009"},{"key":"2025090511543865000_49.4.234.7","unstructured":"Advancing New Standards in Reproductive Health (ANSIRH) . Analysis of medication abortion risk and the FDA report \u201cMifepristone US post-marketing adverse events summary through 6\/30\/2021\". San Francisco ANSIRH; 2022. Available: https:\/\/www.ansirh.org\/sites\/default\/files\/2022-11\/mifepristone_safety_11-15-22_Updated_0.pdf"},{"key":"2025090511543865000_49.4.234.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.03.011"},{"key":"2025090511543865000_49.4.234.9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMsa2109779","article-title":"Abortion safety and use with normally prescribed mifepristone in Canada","volume":"386","author":"Schummers","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090511543865000_49.4.234.10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/AOG.0000000000005253","article-title":"Where do we stand with mifepristone in the United States? Making sense of the madness","volume":"142","author":"French","year":"2023","journal-title":"Obstet Gynecol"},{"key":"2025090511543865000_49.4.234.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1612526"},{"key":"2025090511543865000_49.4.234.12","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2562"},{"key":"2025090511543865000_49.4.234.13","unstructured":"U.S. Food & Drug Administration (FDA) . Information about mifepristone for medical termination of pregnancy through ten weeks gestation. Silver Spring, Maryland U.S. FDA; 2023. Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation#:~:text=In%202021%2C%20after%20conducting%20a,the%20product%20outweigh%20the%20risks"},{"key":"2025090511543865000_49.4.234.14","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.160581"},{"key":"2025090511543865000_49.4.234.15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.contraception.2015.06.014","article-title":"Mifepristone by prescription: a dream in the United States but reality in Australia","volume":"92","author":"Grossman","year":"2015","journal-title":"Contraception"},{"key":"2025090511543865000_49.4.234.16","unstructured":"Te Whatu Ora (Health New Zealand) . Abortion medicines. learn about medications used in abortion services. Ministry of Health; 2022. Available: https:\/\/www.health.govt.nz\/our-work\/regulation-health-and-disability-system\/abortion-services-information-health-practitioners\/abortion-services-primary-and-community-settings\/abortion-medicines"},{"key":"2025090511543865000_49.4.234.17","unstructured":"Australian Government. Department of Health and Aged Care. Therapeutic Goods Administration . Amendments to restrictions for prescribing MS-2 step (Mifepristone and misoprostol). 2023. Available: https:\/\/www.tga.gov.au\/news\/media-releases\/amendments-restrictions-prescribing-ms-2-step-mifepristone-and-misoprostol#:~:text=The%20Therapeutic%20Goods%20Administration%20(TGA,to%2063%20days%20of%20gestation"},{"key":"2025090511543865000_49.4.234.18","unstructured":"Argentina.gob.ar. Ministerio de Salud . La ANMAT autoriz\u00f3 la comercializaci\u00f3n de mifepristona (ANMAT authorised the marketing of mifepristone). Rep\u00fablica Argentina; 2023. Available: https:\/\/www.argentina.gob.ar\/noticias\/la-anmat-autorizo-la-comercializacion-de-mifepristona"},{"key":"2025090511543865000_49.4.234.19","unstructured":"NHK . Oral abortion drug: the subcommittee of the Ministry of Health, Labour and Welfare approved it for the first time in Japan [in Japanese]. Tokyo NHK News Web; 2023. Available: https:\/\/www3.nhk.or.jp\/news\/html\/20230421\/k10014045661000.html"},{"key":"2025090511543865000_49.4.234.20","doi-asserted-by":"crossref","unstructured":"McCurry J . Japan approves abortion pill. Lancet 2023;401. doi:10.1016\/S0140-6736(23)00955-8","DOI":"10.1016\/S0140-6736(23)00955-8"},{"key":"2025090511543865000_49.4.234.21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5694\/mja2.51979","article-title":"Reimagining medical abortion in Australia: what do we need to do to meet women\u2019s needs and ensure ongoing access?","volume":"218","author":"Mazza","year":"2023","journal-title":"Med J Aust"},{"key":"2025090511543865000_49.4.234.22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2023.7790","article-title":"Court intrusion into science and medicine - the mifepristone decisions","volume":"329","author":"Aaron","year":"2023","journal-title":"JAMA"},{"key":"2025090511543865000_49.4.234.23","doi-asserted-by":"crossref","unstructured":"EXPRESSION OF CONCERN: A longitudinal cohort study of emergency room utilization following mifepristone chemical and surgical abortions. Health Serv Res Manag Epidemiol 2023;10. doi:10.1177\/23333928231189400","DOI":"10.1177\/23333928231189400"},{"key":"2025090511543865000_49.4.234.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264494","article-title":"Abortion policy implementation in Ireland: lessons from the community model of care","volume":"17","author":"Mishtal","year":"2022","journal-title":"PLoS ONE"},{"key":"2025090511543865000_49.4.234.25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.31128\/AJGP-01-20-5198","article-title":"Providing medical abortion in general practice: general practitioner insights and tips for future providers","volume":"49","author":"Deb","year":"2020","journal-title":"Aust J Gen Pract"},{"key":"2025090511543865000_49.4.234.26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3122\/jabfm.16.4.290","article-title":"Medical abortion in family practice: a case series","volume":"16","author":"Prine","year":"2003","journal-title":"J Am Board Fam Med"},{"key":"2025090511543865000_49.4.234.27","doi-asserted-by":"crossref","unstructured":"Lai S-L , Cohn A . Efficacy and safety of medical termination of pregnancy in a regional primary care setting. Aust N Z J Obstet Gynaecol 2023:1\u20136. doi:10.1111\/ajo.13738","DOI":"10.1111\/ajo.13738"},{"key":"2025090511543865000_49.4.234.28","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12982"},{"key":"2025090511543865000_49.4.234.29","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/1471-0528.16668","article-title":"Effectiveness, safety and acceptability of no-test medical abortion provided via telemedicine: a national cohort study","volume":"128","author":"Aiken","year":"2021","journal-title":"BJOG"},{"key":"2025090511543865000_49.4.234.30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/AOG.0000000000004312","article-title":"Medication abortion with pharmacist dispensing of mifepristone","volume":"137","author":"Grossman","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2025090511543865000_49.4.234.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063370","article-title":"Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of pharmacists","volume":"12","author":"Zusman","year":"2022","journal-title":"BMJ Open"},{"key":"2025090511543865000_49.4.234.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-021-01144-w","article-title":"Pharmacist dispensing of the abortion pill in Canada: diffusion of innovation meets integrated knowledge translation","volume":"16","author":"Munro","year":"2021","journal-title":"Implement Sci"},{"key":"2025090511543865000_49.4.234.33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.contraception.2021.03.022","article-title":"Expanding access to medication abortion through pharmacy dispensing of mifepristone: primary care perspectives from Illinois","volume":"104","author":"Rasmussen","year":"2021","journal-title":"Contraception"},{"key":"2025090511543865000_49.4.234.34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1471-0528.14646","article-title":"A research agenda for moving early medical pregnancy termination over the counter","volume":"124","author":"Kapp","year":"2017","journal-title":"BJOG"}],"container-title":["BMJ Sexual & Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjsrh-2023-201949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:06:19Z","timestamp":1757099179000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/bmjsrh-2023-201949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjsrh-2023-201949"],"URL":"https:\/\/doi.org\/10.1136\/bmjsrh-2023-201949","relation":{},"ISSN":["2515-1991","2515-2009"],"issn-type":[{"type":"print","value":"2515-1991"},{"type":"electronic","value":"2515-2009"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}